Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug, Nuplazid, highlighting concerns that the medication may not be effective among certain subgroups of dementia patients.…
An ISMP report questions the FDA conclusions that there are no new safety signals with the Parkinson’s disease psychosis drug, Nuplazid.…
New warnings have been added to the warning label for the antipsychotic Rexulti, warning that it carries a risk of gambling addiction, similar to claims made regarding the drug Abilify.…
The FDA has launched a new safety review of the Parkinson’s disease drug Nuplazid, FDA Commissioner Scott Gottlieb told Congress last week.…
More than 700 deaths have been linked to Nuplazid side effects, raising concerns about the safety of the Parkinson’s disease drug.…
The FDA is warning that side effects of Geodon and generic equivalents of the antipsychotic medication may cause a rare but serious skin reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).…
